Navigation Links
Clarient Acquires Applied Genomics, Inc.
Date:12/21/2009

mon stock issued to the former AGI stockholders at closing and up to 3.2 million additional shares of Clarient common stock issuable to the former AGI stockholders contingent upon the satisfaction of certain clinical, commercial and revenue milestones set forth in the merger agreement. The shares issued at closing will be reduced by 440,000 shares that will be placed into an escrow account to cover future indemnity claims.

"AGI's lung cancer pipeline fulfills an important strategic need for Clarient. Having a test that provides us access to the primary lung tumor block much earlier in the diagnostic process will allow Clarient to provide pathologists with critical information at the early stages of therapy decision. It also strengthens our position to gain a greater share of the rapidly increasing EGFR (epidermal growth factor receptor) mutation testing market. The development of lung cancer diagnostics has been slow relative to other cancers; however, we now have a powerful foundation upon which to build a market-leading lung cancer franchise," continued Andrews.

In addition to Pulmotype, AGI has a pipeline of cancer diagnostic, prognostic and theranostic tests at various stages of validation and planned commercialization. Theranostics are a class of tests that assist in the selection of therapies by determining an individual patient's reaction to a specific therapeutic drug. The portfolio of tests includes a theranostic that may predict the response of a patient's cancer to taxane therapy across a variety of cancers, including lung, breast and ovarian. The taxane class of chemotherapeutic agents is widely used, and understanding a patient's propensity to respond before administering this powerful drug will provide clinicians a much needed tool to aid in personalizing cancer treatment. AGI also has a breast cancer panel with proprietary markers that could be included in a future version of Clarient's Insight® Dx, as well as separate
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Clarient to Present at Upcoming Healthcare Investor Conferences in New York City
2. Clarient, BioView Initiate Alliance to Finalize Development and Commercialize Non-Invasive Molecular Diagnostic Test for Early Detection of Lung Cancer
3. Clarient Announces CFO Transition Plan
4. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
5. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
6. U.S. Preventive Medicine Acquires Specialty Disease Management
7. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
8. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim
11. Hospira Acquires Worldwide Rights to Biogeneric Version of Filgrastim and Manufacturing Facility From PLIVA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Research and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ) ... Outlook 2015: Accelerating growth to the next level - ... to their offering. Domestic sales improved ... caused by the market,s reaction to the new drug ... to be healthy, as the momentum continues and improving ...
(Date:3/5/2015)... 2015 Soligenix, Inc. (OTCQB: SNGX) (Soligenix or ... developing products that address unmet medical needs in the ... its President and Chief Executive Officer, Christopher J. ... the 27 th Annual ROTH Conference in ... 10, 2015 at 1:00 PM Pacific Daylight Time (PDT).  ...
(Date:3/5/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/5sqnn3/global_rising ) has ... Outlook 2015" report to their offering. ... after with fresh vigor as new targets , approaches ... to bring a paradigm change in the way diseases ... cell therapy/Regenerative Medicine space. The number of ...
Breaking Medicine Technology:India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3Soligenix to Present at the 27th Annual ROTH Conference 2Soligenix to Present at the 27th Annual ROTH Conference 3Global Pharma Rising Stars Outlook 2015 2
... renarrowing less likely, with no increase in mortality on ... ... have,become widely used for the treatment of stable coronary artery disease,many ... (MI), citing conflicting data about the safety and,effectiveness of drug-eluting stents ...
... to heart ... muscle, ... clot that break loose during percutaneous coronary intervention,(PCI) has failed to show ... coronary syndromes, a condition that,encompasses unstable angina and a type of heart ...
Cached Medicine Technology:Large Study Gives Nod to Drug-Eluting Stents in Heart Attack 2Large Study Gives Nod to Drug-Eluting Stents in Heart Attack 3Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 2Filter Fails to Improve PCI Outcomes in Acute Coronary Syndromes 3
(Date:3/5/2015)... NC (PRWEB) March 05, 2015 ... Physician Assistants’ (AAPA) review of Clearstream, LLC ... determined that Clearstream’s MediDefense line of products—led by ... the AAPA’s Affinity Partner Program. , The AAPA—which ... assistants across all medical and surgical specialties in ...
(Date:3/5/2015)... Diego, CA (PRWEB) March 05, 2015 ... it is now running on 100% pollution-free electricity ... Arcadia Power. , As an Arcadia Power ... Protection Agency’s (EPA) Green Power Partnership requirements, joining ... Starbucks that also purchase clean energy. Earth Source ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 The ... week released a special issue devoted ... field of PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated ... an autoimmune reaction triggered by infections such as ... result in inflammation of the child's brain. This ...
(Date:3/5/2015)... BROOK, Ill. (PRWEB) March 05, 2015 Think ... may be even tougher to get them to brush their ... than 1,300 parents released today by Delta Dental(1) in conjunction ... of parents (45 percent) say getting kids to brush their ... their kids to do. That’s slightly higher than getting children ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Wimbledon ... which provides vascular, echocardiogram and NCV testing, ... as the Chief Medical Officer. Dr. Artel will be ... development of the WimbledonMED program and the continued growth ... passionate about working with Wimbledon Health Partners as a ...
Breaking Medicine News(10 mins):Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 2Health News:Delta Dental Survey Says Parents Have Harder Time Getting Kids to Brush than to Eat Vegetables 3Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 2Health News:Wimbledon Health Partners Appoints Chief Medical Officer to Attain Medicare Market Share 3
... is among the first to describe the prevalence of ... a researcher from the University of California, San Diego ... drug use and accompanying high-risk behavior could lead to ... findings suggest that interventions to reduce high-risk behaviors among ...
... ARBOR, Mich.--- A camper who chases a grizzly but won,t ... to the boss. New research shows that not all risk ... risky and non-risky behaviors. , The survey also shows that ... of Michigan research refutes the standard theories of risk that ...
... specialists at Thomas Jefferson University are examining an innovative ... the procedure, known as Genial Bone Advancement Trephine (GBAT), ... to the tongue is moved forward, to pull the ... the airway space. It is considered an option for ...
... regardless of HDL level, study found , MONDAY, Aug. 27 ... cholesterol do not protect against increased blood pressure ... , The study of more than 21,000 men, ages 20-29 ... than the younger men to blood pressure increases associated with ...
... OAK BROOK, Ill. Using magnetic resonance (MR) images ... related to disease progression and disability in patients with ... the August issue of Radiology. , Based on ... sclerosis more accurately and identify patients at risk for ...
... , UCLA scientists have found the first evidence that ... degeneration yet not increase the risk for estrogen-induced cancers of ... mice infected with the animal equivalent of multiple sclerosis. ... have many choices for anti-inflammatory drugs to help prevent flare-ups ...
Cached Medicine News:Health News:High-risk behaviors could lead to HIV epidemic in Afghanistan 2Health News:High-risk behaviors could lead to HIV epidemic in Afghanistan 3Health News:Not all risk is created equal 2Health News:Jefferson specialists studying innovative surgery for effectively treating sleep apnea 2Health News:New MRI finding sheds light on multiple sclerosis disease progressio 2
For the quantitative in vitro determination of Transferrin in human serum...
For the quantitative in vitro determination of Transferrin in Serum...
Determination of the Thrombin Time by STA Analyzers. Freeze-dried human thrombin (1.5NIH units/mL) with calcium....
Quantitative determination of Fibrinogen (Clauss Method). Freeze-dried human thrombin (~100NIH units/mL) with heparin inhibitor and calcium....
Medicine Products: